Cancer Drugs Approved Based on Biomarkers and Not Tumor Type—FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cancer Drugs Approved Based on Biomarkers and Not Tumor Type—FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers

Published:2018-02-01 Issue:2 Volume:4 Page:157
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Prasad Vinay¹²,Kaestner Victoria¹,Mailankody Sham³

Affiliation:

1. Division of Hematology Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon

2. Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland, Oregon

3. Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Reference9 articles.

1. Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia.;Tiacci;N Engl J Med,2015

2. Improved survival with vemurafenib in melanoma with BRAF V600E mutation.;Chapman;N Engl J Med,2011

3. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations.;Hyman;N Engl J Med,2015

4. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.;Le;Science,2017

5. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.;Chalmers;Genome Med,2017

Cited by 115 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging targeted therapies and strategies to overcome resistance in biliary tract cancers;Critical Reviews in Oncology/Hematology;2024-07

2. A deep profile of gene expression across 18 human cancers;2024-03-17

3. Clinical significance of metastasectomy and pathological response to pembrolizumab in mismatch repair-deficient metastatic colorectal cancer: A retrospective multi-institutional study;2024-03-12

4. Clinical evidence for efficacy of pembrolizumab in MSI-H and TMB-H advanced solid tumor: results from three cancer centers in China;Cancer Immunology, Immunotherapy;2024-03-07

5. Multifaceted perspectives of detecting and targeting solid tumors;International Review of Cell and Molecular Biology;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3